advanced recurrent ovarian cancer pipeline insight

DelveInsight’s, “Advanced Recurrent Ovarian Cancer - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Advanced Recurrent Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Advanced Recurrent Ovarian Cancer: Understanding

Advanced Recurrent Ovarian Cancer: Overview

Advanced Recurrent Ovarian Cancer is the leading cause of death in women diagnosed with gynecological cancers. It is also the fifth most frequent cause of death in women, in general. Most of the cases are diagnosed at an advanced stage, which leads to poor outcomes of this disease. The existing screening tests have a low predictive value contributing further to this misery. Detailed gynecological evaluation along with transvaginal ultrasound and laboratory marker like cancer antigen-125 (CA-125) assay are the key early detection strategies which have shown no significant beneficial effect in the morbidity or mortality of this cancer. Despite advances in treatment, the high recurrence rate and resistance to chemotherapy remain major challenges. As a result, there is a pressing need for the development of more effective screening methods and targeted therapies to improve patient outcomes. Early detection remains critical for better prognosis and to reduce the mortality rates associated with this disease.

 

Advanced recurrent ovarian cancer can present with a range of symptoms, including persistent abdominal pain, bloating, changes in bowel or urinary habits, and unexplained weight loss. Patients may experience fatigue, difficulty eating, back pain, or pain during sex. As the cancer spreads, additional signs may include fluid buildup in the abdomen or around the lungs, bowel obstruction, leg swelling, or new lumps. Skin changes, vaginal discharge, and abnormal bleeding may also occur, reflecting the progression of the disease. In some cases, patients may also develop anemia, leading to paleness and shortness of breath. Persistent or recurrent symptoms that don't improve with treatment should prompt further investigation. These symptoms are often subtle or mistaken for other conditions, which can delay diagnosis and treatment. Early intervention and comprehensive management are crucial for improving the quality of life and survival rates.

 

The pathophysiology of advanced recurrent ovarian cancer involves the uncontrolled growth and spread of malignant ovarian cells. These cancer cells often invade surrounding tissues and organs, leading to the formation of secondary tumors. As the cancer progresses, it can cause fluid accumulation (ascites), obstruct normal organ function, and spread to distant sites such as the lungs or abdomen, disrupting normal physiological processes. The tumor's ability to resist treatment and recur further complicates disease management. The cancer cells can also secrete various growth factors that promote angiogenesis, enabling tumor growth and metastasis. Additionally, the immune system's ability to detect and fight the cancer cells is often compromised, allowing the tumor to persist and spread despite treatment efforts. The formation of chemoresistant cancer stem cells contributes to relapse, while genetic mutations and alterations further complicate treatment strategies. Tumor microenvironment changes, including the presence of immune suppressive cells, also support the cancer's ability to evade immune detection. This multi-faceted resistance mechanism makes advanced recurrent ovarian cancer particularly challenging to treat. 

 

In patients with a high degree of clinical suspicion, radiological imaging, including transvaginal ultrasonography (TVUS), which is highly sensitive and preferred, along with abdominal and pelvic ultrasonography, is typically performed. This provides valuable information about the size, location, and complexity of the ovarian mass. To define tumor extension further, additional imaging techniques such as chest and abdomen pelvis CT scans, pelvic MRI, and/or PET scans may be used. Alongside imaging, the measurement of CA-125 levels is commonly done, as CA-125 is elevated in most epithelial ovarian cancers, although it is elevated in only half of early-stage epithelial ovarian cancers. For many years, the optimal treatment for advanced ovarian cancer has been surgical cytoreduction followed by intravenous platinum and taxane chemotherapy on a three-week schedule.

 

"Advanced Recurrent Ovarian Cancer- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Recurrent Ovarian Cancer pipeline landscape is provided which includes the disease overview and Advanced Recurrent Ovarian Cancer treatment guidelines. The assessment part of the report embraces, in depth Advanced Recurrent Ovarian Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Recurrent Ovarian Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Recurrent Ovarian Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Recurrent Ovarian Cancer.

 

Advanced Recurrent Ovarian Cancer Emerging Drugs Chapters

This segment of the Advanced Recurrent Ovarian Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Advanced Recurrent Ovarian Cancer Emerging Drugs

• 2X-121: Allarity Therapeutics

Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the Wnt signaling pathway. Aberrant Wnt/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking Wnt pathway activation, stenoparib’s unique therapeutic action shows potential as a promising therapeutic. Allarity has exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. Some approved PARP inhibitors have recently been shown to be associated with less favorable survival outcomes than initially established. Allarity’s Phase II trial data for stenoparib to date shows that the drug has much less myelotoxicity than the FDA approved PARP inhibitors. Currently, the drug is in the Phase II stage of its development for the treatment of Advanced Recurrent Ovarian Cancer.

 

• A2B694: A2 Biotherapeutics Inc.

A2B694 is a Tmod™ chimeric antigen receptor (CAR) T cell therapy targeting tumors that express mesothelin (MSLN) but lack the HLA-A*02 antigen. A2B694 is the second autologous cell therapy in clinical development by A2 Bio using its proprietary Tmod™ platform.  The Tmod™ platform utilizes a dual-receptor design consisting of an activator that targets tumor cells and a blocker that protects normal cells. This dual-receptor design is intended to provide selective killing of tumor tissues that express mesothelin and have lost the HLA-A*02 gene permanently.  This novel design is aimed at tackling the fundamental challenge in solid tumor cancer medicines – the ability to selectively kill tumor cells and protect normal cells. Currently, the drug is in Phase I/II stage of its development for the treatment of Advanced Recurrent Ovarian Cancer.

 

• ATX-295: Accent Therapeutics

Accent's ATX-295 program is a potential best-in-class inhibitor for KIF18A which may address a large patient population across several cancer indications, including ovarian and triple negative breast cancer (TNBC). KIF18A is a mitotic kinesin motor protein critical for cell division in select tumors with chromosomal instability, but not in healthy cells. KIF18A inhibitor treatment results in rapid cell death for cancers with an abnormal number of chromosomes (aneuploid) in vitro and in vivo, while cells with normal numbers of chromosomes (euploid) are unaffected. Currently, the drug is in Phase I stage of its development for the treatment of Advanced Recurrent Ovarian Cancer.

Further product details are provided in the report……..

 

Advanced Recurrent Ovarian Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Advanced Recurrent Ovarian Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major  Players in Advanced Recurrent Ovarian Cancer

There are approx. 10+ key companies which are developing the therapies for Advanced Recurrent Ovarian Cancer. The companies which have their Advanced Recurrent Ovarian Cancer drug candidates in the most advanced stage, i.e. Phase II include, Allarity Therapeutics.

 

Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Advanced Recurrent Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Advanced Recurrent Ovarian Cancer: Pipeline Development Activities 

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Advanced Recurrent Ovarian Cancer therapeutic drugs key players involved in developing key drugs. 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Recurrent Ovarian Cancer drugs.

 

Advanced Recurrent Ovarian Cancer Report Insights

• Advanced Recurrent Ovarian Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Advanced Recurrent Ovarian Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Advanced Recurrent Ovarian Cancer drugs?
• How many Advanced Recurrent Ovarian Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Recurrent Ovarian Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Advanced Recurrent Ovarian Cancer therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Advanced Recurrent Ovarian Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?